Search - tctmd.com

Displaying 181 - 200 of 4990

Sort: Relevancy | Date

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

Patient and Lesion Selection for BRS: What Is Optimal and What Should Be Avoided?

Presenter: Stephen G. Ellis, Patrick W. Serruys, Christoph K. Naber

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

BRS Benchtop Findings: Implications for Implantation Techniques

Presenter: Stephen G. Ellis, Patrick W. Serruys, Nicolas Foin

November 01, 2016

Presentation TCT 2016

Retrograde Step-by-step

Presenter: Alfredo R. Galassi, Masahiko Ochiai, James C. Spratt

November 01, 2016

Presentation TCT 2016

Impact of Different PLLA Polymers and BRS Construction on Implant Technique: From Absorb to DESolve to Fantom to Manli and More

Presenter: Stephen G. Ellis, Patrick W. Serruys, Alexandre Abizaid

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

Novel DCB Coatings and Alternative Drugs: Are We Reaching the End of the Road?

Presenter: Fernando Alfonso, Juan F. Granada

November 01, 2016

Presentation TCT 2016

Complications Related to Contrast and Commonly Used Medications

Presenter: Giora Weisz, Payam Dehghani

November 01, 2016

Presentation TCT 2016

Case Resolution: What Was Done

Presenter: John A. Bittl, David J. Maron, Kishore J. Harjai

November 01, 2016

Presentation TCT 2016

The Case for Surgery

Presenter: Michael A. Borger, Vinod H. Thourani, Martin Misfeld

November 01, 2016

Presentation TCT 2016

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Presenter: Sanjay Kaul, Jeffrey J. Popma, John D. Puskas

November 01, 2016

Presentation TCT 2016

Debate: Should Complete Revascularization in STEMI and Multivessel Disease Be Performed During the Index Procedure? Yes, in Most Patients, to Improve Prognosis and Reduce Costs!

Presenter: Adrian P. Banning, Nick Curzen, Keith G. Oldroyd

November 01, 2016

Presentation TCT 2016

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Presenter: Gregg W. Stone, Ron Waksman, John A. Ambrose

November 01, 2016

Presentation TCT 2016

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

Presenter: John A. Bittl, David J. Maron, John A. Spertus

November 01, 2016

Presentation TCT 2016

Methods and Technologies to Improve DCB Outcomes: Does the Data Support Their Use?

Presenter: Fernando Alfonso, Juan F. Granada, Azeem Latib

November 01, 2016

Presentation TCT 2016

Debate: Should Complete Revascularization in STEMI and Multivessel Disease Be Performed During the Index Procedure? No, in the Middle of the Night and With Complex Anatomy ... Are You Kidding?!

Presenter: Adrian P. Banning, Nick Curzen, Herbert D. Aronow

November 01, 2016

Presentation TCT 2016

The Case for Transcatheter Therapy

Presenter: Michael A. Borger, Vinod H. Thourani, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Presenter: Gregg W. Stone, Ron Waksman, Jonathan Leor

November 01, 2016

Advertisement

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Patient and Lesion Selection for BRS: What Is Optimal and What Should Be Avoided?

FDA Perspectives on Short DAPT IDE Trials

BRS Benchtop Findings: Implications for Implantation Techniques

Retrograde Step-by-step

Impact of Different PLLA Polymers and BRS Construction on Implant Technique: From Absorb to DESolve to Fantom to Manli and More

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Novel DCB Coatings and Alternative Drugs: Are We Reaching the End of the Road?

Complications Related to Contrast and Commonly Used Medications

Case Resolution: What Was Done

The Case for Surgery

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Debate: Should Complete Revascularization in STEMI and Multivessel Disease Be Performed During the Index Procedure? Yes, in Most Patients, to Improve Prognosis and Reduce Costs!

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

Methods and Technologies to Improve DCB Outcomes: Does the Data Support Their Use?

Debate: Should Complete Revascularization in STEMI and Multivessel Disease Be Performed During the Index Procedure? No, in the Middle of the Night and With Complex Anatomy ... Are You Kidding?!

The Case for Transcatheter Therapy

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content